 Warren Capell
Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rivaroxaban | 12 | 2022 | 208 | 2.350 |
Why?
| | Peripheral Arterial Disease | 12 | 2022 | 377 | 1.850 |
Why?
| | Factor Xa Inhibitors | 6 | 2021 | 138 | 1.310 |
Why?
| | Lower Extremity | 9 | 2022 | 335 | 1.260 |
Why?
| | Aspirin | 10 | 2022 | 334 | 1.250 |
Why?
| | Endovascular Procedures | 5 | 2022 | 276 | 0.980 |
Why?
| | Beneficence | 1 | 2021 | 18 | 0.780 |
Why?
| | Thrombosis | 2 | 2022 | 309 | 0.780 |
Why?
| | Hypertriglyceridemia | 3 | 2006 | 39 | 0.770 |
Why?
| | Research Subjects | 1 | 2021 | 40 | 0.760 |
Why?
| | Personal Autonomy | 1 | 2021 | 41 | 0.760 |
Why?
| | Informed Consent | 2 | 2021 | 163 | 0.760 |
Why?
| | Patient Selection | 2 | 2021 | 676 | 0.700 |
Why?
| | Ischemia | 5 | 2022 | 374 | 0.660 |
Why?
| | Outpatients | 1 | 2021 | 325 | 0.630 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2022 | 402 | 0.620 |
Why?
| | Venous Thromboembolism | 3 | 2023 | 234 | 0.500 |
Why?
| | Hospitalization | 2 | 2021 | 1785 | 0.430 |
Why?
| | Lipoproteins | 4 | 2010 | 162 | 0.430 |
Why?
| | Lipoprotein Lipase | 2 | 2010 | 68 | 0.420 |
Why?
| | Risk Assessment | 1 | 2021 | 3057 | 0.400 |
Why?
| | Hypolipidemic Agents | 3 | 2006 | 86 | 0.390 |
Why?
| | Double-Blind Method | 6 | 2021 | 1687 | 0.380 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2010 | 31 | 0.370 |
Why?
| | Hemorrhage | 5 | 2023 | 623 | 0.300 |
Why?
| | Triglycerides | 3 | 2010 | 519 | 0.290 |
Why?
| | Drug Therapy, Combination | 5 | 2021 | 965 | 0.280 |
Why?
| | Glucose | 1 | 2010 | 953 | 0.260 |
Why?
| | Myocardial Infarction | 2 | 2022 | 968 | 0.250 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2010 | 167 | 0.230 |
Why?
| | Fenofibrate | 1 | 2003 | 24 | 0.220 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 79 | 0.220 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 44 | 0.220 |
Why?
| | Muscle, Skeletal | 2 | 2010 | 1515 | 0.220 |
Why?
| | Male | 19 | 2023 | 57801 | 0.210 |
Why?
| | Multicenter Studies as Topic | 2 | 2021 | 253 | 0.210 |
Why?
| | Middle Aged | 13 | 2023 | 27617 | 0.210 |
Why?
| | Drug-Eluting Stents | 1 | 2021 | 66 | 0.200 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 78 | 0.200 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2021 | 49 | 0.190 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 208 | 0.190 |
Why?
| | Placebos | 1 | 2021 | 202 | 0.190 |
Why?
| | Paclitaxel | 1 | 2021 | 195 | 0.190 |
Why?
| | Clinical Trials as Topic | 3 | 2021 | 969 | 0.190 |
Why?
| | Female | 17 | 2023 | 61564 | 0.190 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4596 | 0.190 |
Why?
| | Humans | 27 | 2023 | 118972 | 0.190 |
Why?
| | Extremities | 1 | 2021 | 113 | 0.180 |
Why?
| | Vasodilation | 1 | 2003 | 457 | 0.180 |
Why?
| | Cause of Death | 1 | 2021 | 380 | 0.170 |
Why?
| | Subacute Care | 1 | 2019 | 74 | 0.160 |
Why?
| | Vascular Surgical Procedures | 1 | 2021 | 262 | 0.160 |
Why?
| | Nursing Homes | 1 | 2019 | 130 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2021 | 310 | 0.160 |
Why?
| | Treatment Outcome | 6 | 2022 | 9342 | 0.160 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2018 | 62 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 1945 | 0.150 |
Why?
| | Hospital Mortality | 1 | 2021 | 814 | 0.140 |
Why?
| | Health Services Research | 1 | 2019 | 385 | 0.140 |
Why?
| | Lipoproteins, LDL | 1 | 1996 | 138 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1244 | 0.130 |
Why?
| | Skilled Nursing Facilities | 1 | 2017 | 122 | 0.130 |
Why?
| | Consensus | 1 | 2017 | 534 | 0.130 |
Why?
| | Fibrinolytic Agents | 1 | 2017 | 238 | 0.130 |
Why?
| | Insulin Resistance | 3 | 2013 | 1180 | 0.120 |
Why?
| | Ethics, Research | 1 | 2014 | 31 | 0.120 |
Why?
| | Anticoagulants | 3 | 2023 | 559 | 0.120 |
Why?
| | Societies, Medical | 1 | 2017 | 703 | 0.110 |
Why?
| | Disease Management | 1 | 2017 | 571 | 0.110 |
Why?
| | Stroke | 1 | 2021 | 1047 | 0.110 |
Why?
| | Cardiovascular Diseases | 2 | 2021 | 1798 | 0.110 |
Why?
| | Caspase 1 | 1 | 2013 | 143 | 0.110 |
Why?
| | Interleukin-18 | 1 | 2013 | 228 | 0.100 |
Why?
| | Aged | 8 | 2022 | 19657 | 0.100 |
Why?
| | Heparin | 2 | 2023 | 230 | 0.100 |
Why?
| | Biomedical Research | 1 | 2017 | 612 | 0.100 |
Why?
| | Research Design | 1 | 2017 | 969 | 0.100 |
Why?
| | Interleukin-1beta | 1 | 2013 | 379 | 0.100 |
Why?
| | Postoperative Complications | 1 | 2021 | 2235 | 0.090 |
Why?
| | Arteries | 2 | 2022 | 250 | 0.090 |
Why?
| | Transfection | 2 | 2010 | 888 | 0.090 |
Why?
| | Lactones | 1 | 2010 | 57 | 0.090 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2010 | 31 | 0.090 |
Why?
| | Myoblasts | 1 | 2010 | 75 | 0.090 |
Why?
| | Dietary Fats | 2 | 2010 | 322 | 0.090 |
Why?
| | Diet, Fat-Restricted | 2 | 2010 | 76 | 0.090 |
Why?
| | Hypercholesterolemia | 1 | 2010 | 93 | 0.090 |
Why?
| | Obesity | 2 | 2013 | 2746 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 842 | 0.080 |
Why?
| | Inflammation | 2 | 2023 | 2566 | 0.080 |
Why?
| | Palliative Care | 1 | 2014 | 629 | 0.080 |
Why?
| | Blotting, Western | 1 | 2010 | 1194 | 0.080 |
Why?
| | Adult | 5 | 2021 | 31512 | 0.070 |
Why?
| | Simvastatin | 1 | 2006 | 65 | 0.070 |
Why?
| | Temperance | 1 | 2005 | 15 | 0.070 |
Why?
| | Cross-Over Studies | 2 | 2006 | 456 | 0.070 |
Why?
| | Weight Loss | 1 | 2010 | 655 | 0.060 |
Why?
| | Anticholesteremic Agents | 1 | 2006 | 130 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2006 | 360 | 0.060 |
Why?
| | Treatment Failure | 1 | 2005 | 341 | 0.060 |
Why?
| | Cell Line | 1 | 2010 | 2707 | 0.060 |
Why?
| | Incidence | 2 | 2021 | 2424 | 0.060 |
Why?
| | Heart Failure | 1 | 2017 | 1969 | 0.060 |
Why?
| | Thromboplastin | 1 | 2023 | 68 | 0.060 |
Why?
| | Forearm | 1 | 2003 | 117 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 387 | 0.050 |
Why?
| | Vesicular Transport Proteins | 1 | 2003 | 84 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 8 | 0.050 |
Why?
| | Fasting | 1 | 2003 | 264 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2005 | 394 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2003 | 418 | 0.050 |
Why?
| | Postmenopause | 1 | 2003 | 305 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 180 | 0.050 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2003 | 454 | 0.050 |
Why?
| | Internationality | 1 | 2020 | 152 | 0.050 |
Why?
| | Lipid Metabolism | 1 | 2003 | 477 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2005 | 652 | 0.040 |
Why?
| | Mice | 3 | 2013 | 15520 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2003 | 551 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 67 | 0.040 |
Why?
| | Acute Disease | 1 | 2021 | 940 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 310 | 0.040 |
Why?
| | Algorithms | 1 | 2006 | 1541 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1125 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1440 | 0.040 |
Why?
| | Proteins | 1 | 2003 | 938 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1166 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2003 | 1055 | 0.040 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 316 | 0.040 |
Why?
| | Arteriosclerosis | 1 | 1996 | 88 | 0.040 |
Why?
| | Patient Safety | 1 | 2019 | 281 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 9000 | 0.030 |
Why?
| | Particle Size | 1 | 1996 | 345 | 0.030 |
Why?
| | Patient Transfer | 1 | 2017 | 143 | 0.030 |
Why?
| | Reference Values | 1 | 1996 | 774 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 331 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2014 | 44 | 0.030 |
Why?
| | Animals | 3 | 2013 | 33381 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2006 | 2174 | 0.030 |
Why?
| | Research Personnel | 1 | 2014 | 158 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 5116 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2013 | 247 | 0.030 |
Why?
| | Prospective Studies | 1 | 2022 | 6471 | 0.020 |
Why?
| | Diet, Reducing | 1 | 2010 | 81 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 963 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2010 | 153 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 934 | 0.020 |
Why?
| | Communication | 1 | 2014 | 761 | 0.020 |
Why?
| | Phenotype | 1 | 1996 | 3003 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1781 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 447 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 2680 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2003 | 12978 | 0.020 |
Why?
| | Dyslipidemias | 1 | 2006 | 162 | 0.020 |
Why?
| | Munc18 Proteins | 1 | 2003 | 23 | 0.010 |
Why?
| | SNARE Proteins | 1 | 2003 | 37 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 6412 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2003 | 192 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 770 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 982 | 0.010 |
Why?
| | Insulin | 1 | 2010 | 2162 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2003 | 2025 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 4077 | 0.010 |
Why?
| | Blood Glucose | 1 | 2003 | 1939 | 0.010 |
Why?
|
|
Capell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|